US Valion Bio Initiates Safety Study of Entolimod for Radiation-Induced Gastrointestinal Injury
US biotechnology company Valion Bio announced on August 12 that the safety study of its investigational therapeutic candidate Entolimod for radiation-induced gastrointestinal injury is scheduled to commence this week. The study is being advanced by the Armed Forces Radiobiology Research Institute (AFRRI) under a contract with the National Institute of Allergy and Infectious Diseases (NIAID), as part of a government-funded research program. According to the company's disclosure, Entolimod has been delivered to AFRRI, the study has received approval from the Institutional Animal Care and Use Committee (IACUC), and the experimental animals are currently in the pre-dosing acclimation phase. The safety study will confirm the tolerability of Entolimod in the animal strain used by AFRRI...
2026-08-13
